US regulators have approved Eli Lilly’s Zepbound to treat adults with both sleep apnoea and obesity, marking a victory for the drugmaker as it seeks to expand its blockbuster weight-loss drugs franchise.
The Food and Drug Administration on Friday cleared the way for the drug to be used to treat moderate-to-severe obstructive sleep apnoea in obese adults, the company said in a statement late on Friday.
FDA approval puts Eli Lilly ahead in the sector-wide race to build on rocketing US demand for anti-obesity medications, which analysts forecast could result in more than $100bn in annual sales by 2030.
您已阅读30%（604字），剩余70%（1421字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。